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We demonstrate that PMA exhibits multiple ffects on fMetLeuPhe and ionophore-mediated s cretion from 
rabbit and human eutrophils: (i) Inhibition of receptor-mediated s cretion appears to take place at an early 
stage in the stimulus-secretion coupling sequence since PMA inhibits the formation of phosphatidate. (ii)
Protein phosphorylation is observed with both PMA and fMetLeuPhe and the extent of phosphorylation 
is additive in the presence of both stimuli. (iii) Another possible site of regulation by PMA lies distal to 
the rise in cytosolic Ca 2+ .This is indicated by the enhancement or inhibition by PMA of the A23187-induced 
secretory response at low and high external Ca2+ concentrations, respectively. 
Phorbol ester Ca2+ fMetLeuPhe Neutrophil Exocytosis Protein phosphorylation Phosphatidate 
1. INTRODUCTION 
Activation of neutrophils with fMetLeuPhe 
stimulates a variety of cell functions, e.g. 
chemotaxis, aggregation, superoxide generation, 
formation of arachidonic acid derived metabolites 
and the exocytotic release of secretory granules 
[1,2]. Receptor occupation is coupled to the 
hydrolysis of phosphatidylinositol bisphosphate 
generating two intracellular messengers [3], IP3 (a 
mediator of Ca2+ mobilisation from intracellular 
stores [4]) and DG (an activator of protein kinase 
C [5]). It has been proposed that these two signall- 
ing pathways, both independently (in some in- 
stances) and synergistically, may be responsible for 
activating the ligand-induced responses of many 
cell types [6]. 
The two signalling pathways can be activated in- 
dependently by the use of Ca2+ ionophores and 
Abbreviations: PDA, &-phorbol 12,13-didecanoate; 
PMA, 4@-phorbol l&&myristate 13wacetate; IP3, ino- 
sitol 1,4,Strisphosphate; DG, diacylglycerol; fMet, for- 
mylmethionyl; PBS, NaCl (0.154 M) containing 10 mM 
Na phosphate (pH 7) 
phorbol esters. Ca2+ ionophores (A23 187 or 
ionomycin) alone can activate many of the 
neutrophil processes including secretion from 
azurophilic granules [7,8]. Phorbol esters, such as 
PMA, which do not raise the intracellular Ca2+ 
levels [9], are also effective agonists for some of 
the neutrophil functions due to their ability to 
mimic DG and so directly activate protein kinase C 
[5]. PMA is a good stimulus for both superoxide 
generation and secretion from the specific granules 
[lo-121. However secretion from the azurophil 
granules is slow and only becomes ignificant over 
a period of 30 min [10,12]. 
In cells responding normally to stimulation of 
cell surface receptors, the rise in cytosolic Ca2+ and 
the generation of DG occur simultaneously. 
Therefore, one might expect to be able to achieve 
a full activation response by artificial provision of 
both signals at concentrations which when applied 
alone are insufficient. In this way it has been 
shown that subthreshold concentrations of Ca2+ 
ionophores and PMA can synergise to cause 
superoxide generation [13,141, chemotaxis [151 and 
release from both specific [11,14] and azurophil 
granules [14,16-181. 
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Here we present evidence that PMA has multiple PBS for the determination of enzyme secretion and 
effects on secretion of azurophil granules phospholipid analysis, The lipids were extracted 
stimulated by either the agonist fMetLeuPhe or the from the pelleted cells with chloroform/methanol 
Ca2+ ionophore. The combination of PMA and [19] and the samples analysed by TLC as described 
Ca2’ ionophore can lead to potentiation or inhibi- 1201. SDS-polyacryl~ide gel electrophoresis was 
tion of secretion. PMA also inhibits the formation carried out in a discontinuous ystem using a 10% 
of phosphatidate due to fMetLeuPhe. We con- separating gel (pH 8.8) and 3% stacking gel (pH 
clude that PMA not only inhibits events subse- 6.8) as described by Laemmli [21j. Autoradio- 
quent to increases in cytosol Ca*” but also inhibits graphs of the stained and dried gels were analysed 
at the level of the receptor. on a Joyce-Loebel Chromoscan. 
2. MATERIALS AND METHODS 
Rabbit peritoneal exudate and human peripheral 
neutrophils were prepared as described [2,19]. 
They were suspended at 10’ cells *ml-’ in a buf- 
fered salt solution (pH 7.2) which comprised 
137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1 mM 
CaClz (unless otherwise stated), 20 mM Hepes, 
5.6 mM glucose and 1 mg * ml-’ bovine serum 
albumin. The cells were incubated for 15 min at 
37OC before addition of cytochalasin B (final con- 
centration 5 pg *ml-‘). After 2 min the cells were 
transferred to solutions cont~ning appropriate 
concentrations of ionophore A23187, fMetLeuPhe 
or PMA, either individually or in combination. In 
some experiments the cells were pretreated with 
PMA (for the times indicated in the legends to figs 
1 and 2) before transfer to A23 187 or fMetLeuPhe. 
After the times indicated, the reactions were 
quenched by addition of ice-cold PBS. Following 
centrifugation, samples of the supernatants were 
removed for measurement of secreted ,@- 
glucuronidase [2]. The experiments presented in 
figs 1-3 and tables 1 and 3 were done in duplicate 
and the d~erminations did not differ by more than 
5%. 
Molecular mass markers (12-78000 Da range) 
were obtained from BDH, Poole, England. All 
other reagents were of the best analytical grades 
available and were obtained from BCL (Lewes) or 
Sigma (Poole). 
3. RESULTS 
We preincubated rabbit neutrophils with lo-’ M 
PMA for 5 min and then challenged the cells with 
A23187 in the presence of 50/~M or 1 mM Ca*‘. 
The rationale for comparing different external 
Ca2+ was to induce submaximal and maximal 
degrees of secretion [7], A typical experiment is 
presented in fig. 1, and results from four individual 
experiments (+ SE) are pooled in table 1. In the 
presence of 5OrM Ca*+, the maximal extent of 
secretion due to A23187 alone (in the range 
For the experiments of fig.3 and table 2, the rab- 
bit neutrophils were resuspended at IO’ cells- ml-’ 
in buffer made up as described but containing 
bovine serum albumin at 0.25 mg - ml-‘. They were 
incubated for 1 h at 37°C with 1 mCi * ml-’ 
[‘*PIphosphate. The cells were then washed twice, 
cytochalasin B was added and after 2 min the cells 
were transferred to an equal volume of buffer con- 
taining stimulating ligands as indicated. For the 
analysis of protein phosphorylation, duplicate 
samples were quenched after 1 min by addition of 
5% (final concentration) trichloroacetic acid. 
Triplicate samples were quenched with ice-cold 
I 0.025 0*25 25 
g A23187pM) 
I? 
Fig. 1. ReIatio4ship of extracellular calcium to the effects 
of PMA on A23187-mediated~-~ucuronidase secretion. 
Rabbit neutrophils were preincubated in the presence 
(open symbols) and absence (solid symbols) of lo-’ M 
PMA for 3 min before transfer to solutions containing 
A23187 at concentrations indicated and calcium at 
50 PM (o,O) and I mM (A , A) for a further 3 min at 
37°C. 
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Table 1 
Enhancement and inhibition of 
glucuronidase secretion 
A23 187-induced fl- 
by PMA 
PDA not only fails to enhance any,&glucuronidase 
secretion due to low concentrations of 
fMetLeuPhe but also has no inhibitory effect at 
higher ligand concentrations. Fig.Zb also shows 
that the inhibition by PMA of fMetLeuPhe- 
mediated activation is common to both rabbit 
peritoneal and human peripheral neutrophils. 
May 1986 
Extracellular Ca2’: 
(90 fi-glucuronidase secretion 
50 /IM 1 mM 
A23187 36 f 6 (4) 63 f 6 (4) 
Plus PMA lo-’ M 44 * 4 (4) 38 f 4 (4) 
The ionophore was used at 2.5 /tM, a concentration 
sufficient to induce maximal secretion at any 
concentration f Ca2+. Results expressed as means f SE 
(n, number of separate xperiments) 
0.025-2.5 ,uM) is moderate and can be potentiated 
by PMA. In contrast, the higher level of secretion 
due to 1 mM Ca” is inhibited by PMA. 
We next examined the effect of PMA on 
fMetLeuPhe stimulated secretion. Whilst the com- 
bination of PMA with subthreshold levels of 
fMetLeuPhe causes a slight enhancement of ,8- 
glucuronidase secretion, PMA inhibits the secre- 
tion due to saturating concentrations of the ligand 
(fig.2a). This inhibition of receptor-mediated 
degranulation is even more extensive if the cells are 
preincubated with PMA before challenging with 
fMetLeuPhe (fig.2b). The inactive phorbol ester 
-10 
fMLP IIcqMl 
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Fig.2. Inhibition by PMA of ,%glucuronidase secretion 
due to fMetLeuPhe in rabbit and human neutrophils. (a) 
Rabbit neutrophils were stimulated with different 
concentrations of fMetLeuPhe for 5 min in the absence 
(0) and presence of lo-“ M (A) and lo-’ M PMA (m). 
(b) Human neutrophils were preincubated with either 
buffer (o), PMA (m) or PDA (0) (both at lo-’ M) for 
15 min at 37°C before being stimulated with different 
concentrations of fMetLeuPhe for 5 min. 
To determine at what level PMA inhibits 
fMetLeuPhe-induced responses we investigated its 
effect on phosphatidate formation. This allowed 
us to monitor the effect of PMA on the generation 
of DG from the hydrolysed inositol lipids, a pro- 
cess closely associated with the initial events in the 
generation of second messenger molecules. Rabbit 
neutrophils prelabelled to equilibrium with 32P 
were treated with PMA and fMetLeuPhe, either 
individually or in combination. The ,8- 
glucuronidase release stimulated by the combina- 
tion of fMetLeuPhe (lo-’ M) and PMA (lo-’ M) 
was inhibited by approx. 40% compared to the 
release stimulated by the ligand alone. This cor- 
relates with the inhibition by PMA of 
fMetLeuPhe-induced formation of phosphatidate 
(table 2). 
As PMA is an activator of protein kinase C we 
considered the possibility that the inhibition due to 
PMA was caused by phosphorylation of some 
essential regulatory protein. This was examined by 
determining the profile of 32P incorporation into 
proteins from cells treated for 1 min with either 
PMA, fMetLeuPhe or their combination. Both 
PMA and fMetLeuPhe induced similar profiles of 
protein phosphorylation, the difference being in 
Table 2 
Inhibition by PMA of &glucuronidase secretion and 
phosphatidate formation due to fMetLeuPhe 
B-Glucuronid- Phosphatidate 
ase (olo formation 
secretion) (vo of control) 
Control 0 (100) 
fMetLeuPhe (lo-’ M) 68 f 10 (6) 192 + 16 (7) 
PMA (lo-’ M) 5 f 1 (6) 93 f 6 (7) 
fMetLeuPhe plus 
PMA 48 f 8 (6) 147 + 16 (7) 
Results expressed as means f SE (n, number of separate 
experiments) 
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Fig.3. Protein phosphorylation in rabbit neutrophils 
after stimulation with PMA and fMetLeuPhe, 
individually and in combination. Rabbit neutrophils, 
labelled with [3ZP]phosphate, were stimulated for 1 min 
at 37’C. (a) Control; (b) lo-’ M PMA; (c) lo-’ M 
fMetLeuPhe; (d) lo-’ M PMA plus lo-’ M 
fMetLeuPhe. After quenching with ice-cold 5% 
trichloroacetic acid the precipitates were pelleted and 
then washed with PBS before solubilisation in SDS 
sample buffer. After SDS-polyacrylamide gel 
electrophoresis the dried gel was autoradiographed for 3 
days (A) and the lanes scanned with a Joyce-Loebl 
Chromoscan (B). The molecular masses of the bands of 
interest are indicated. 
Table 3 
Increase in incorporation of [32P]phosphate into 
neutrophil proteins on stimulation with fh4etLeuPhe 
and PMA individually and in combination 
Control 
fMetLeuPhe 
PMA 
fMetLeuPhe plus 
88 kDa 64 kDa 47 kDa 
100 100 100 
163 f 4 140 + 10 138 f 12 
121 f 4 122 + 6 140 f 3 
PMA 207 + 6 158 f 13 201 + 24 
Data represent percentage increase of peak areas 
(means + SE; n = 6 separate experiments) 
the degree of phosphorylation found in individual 
bands (fig.3, table 3). The combination of the 
stimuli led to a particularly marked enhancement 
in the phosphorylation of proteins of iWr 88000, 
64000 and 47000. 
4. DISCUSSION 
The pattern of fMetLeuPhe-mediated secretion 
of azurophil granules can be mimicked under cer- 
tain circumstances by artificial enhancement of 
cytosol Ca2+ and activation of protein kinase C. 
The potentiation which we have observed is rather 
modest and is comparable to that reported by some 
[16,17] but less than that recorded by others 
[14,18]. Activation of protein kinase C by PMA 
can also lead to inhibition of the fMetLeuPhe- 
mediated and the Ca2+-mediated responses. It 
would appear that the inhibition of receptor- 
mediated events by PMA takes place at a stage in 
the secretory process prior to the elevation of 
cytosol Ca 2+. This conclusion is supported by the 
observation that phosphatidate production, and 
hence presumably phosphatidylinositol bisphos- 
phate hydrolysis, is also inhibited by PMA. It has 
been reported that PMA can inhibit the receptor- 
mediated rise in cytosolic Ca2+ [l&22] cor- 
roborating the above conclusion that it interferes 
with the generation of IP3. Inhibition of receptor- 
stimulated inositol lipid metabolism by PMA has 
been reported for PC12 cells [23], platelets [24,25], 
astrocytoma cells [26] and smooth muscle [27-291 
and may reflect a common feedback control 
mechanism in Ca2+ -mobilising receptors. 
To inhibit the hydrolysis of phosphatidylinositol 
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bisphosphate it may be necessary to uncouple the 
receptor from its catalytic unit, polyphospho- 
inositide phosphodiesterase, and this could be 
achieved by PMA-induced phosphorylation of 
either the receptor itself or the guanine nucleotide 
regulatory protein (Np) which couples the two [30]. 
Enhanced phosphorylation of several protein 
bands occurs when rabbit neutrophils are challeng- 
ed with the combination of fMetLeuPhe and PMA 
(fig.3) and one of these has an A& of 64000 which 
is similar to the reported M, of the formylpeptide 
receptor [3 l-331. Furthermore, PMA-induced 
phosphorylation of receptors [34-361 and G- 
proteins [37-391 as a means of modulating signal 
transduction has now been reported for a number 
of different systems and may reflect a role for pro- 
tein kinase C in the activation and termination of 
cellular secretory processes. 
PMA may also act at a second site in the train 
of events leading to exocytosis of azurophil 
granules since it is an inhibitor of ionophore- 
induced secretion and the secretion due to Ca*+ 
buffers introduced into permeabilised neutrophils 
[40]. Alternatively it is possible that PMA prevents 
the formation of the products of arachidonic acid 
metabolism arising from ionophore stimulation. 
A23 187 can stimulate production of leukotriene B4 
[41], PAF [42] (both stimulatory for neutrophils) 
and 5-HETE which potentiates their actions [43]. 
In this case the inhibition by PMA of the azurophil 
granule secretion induced by optimal levels of 
A23187 and Ca*+ may parallel the inhibition by 
PMA of fMetLeuPhe-induced secretion. Against 
this, there is evidence that the secretion due to 
A23187 is quite independent of leukotriene [44] or 
5-HETE [45] synthesis. 
In conclusion, we find that PMA can either 
synergise with or inhibit secretion of ,& 
glucuronidase, depending on the conditions. In 
particular, it enhances ecretion when the extent of 
Ca*+ elevation due to the ionophore is limited, but 
becomes inhibitory in the face of higher levels of 
cytosol Ca*+. We also find that PMA has effects 
prior to the rise in cytosol Ca*+ since the inhibition 
of fMetLeuPhe-mediated ,%glucuronidase secre- 
tion correlates with an equivalent inhibition of 
phosphatidate formation and hence, presumably 
IP3 generation. Whether all the effects of PMA 
can be attributed to its ability to activate protein 
kinase C is not known. 
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